NIAID: Three-Dose Hepatitis B Vaccine Regimen Protects People with HIV
The National Institute of Allergy and Infectious Diseases (NIAID) announced that a three-dose course of the hepatitis B vaccine, HEPLISAV-B, fully protects adults living with HIV who have never been vaccinated against, or infected with, the hepatitis B virus (HBV), according to study findings presented on Friday, Oct. 21, at the Infectious Diseases (ID) Week conference in Washington, D.C. The NIAID, part of the National Institutes of Health, is sponsoring the ongoing Phase 3 ACTG A5379 clinical study. HBV is spread primarily through sexual contact and through the sharing of contaminated needles. It can cause chronic hepatitis B infection
